RT Journal Article
SR Electronic
T1 Elucidating the phenotypic variability associated with the polyT tract and TG repeats in CFTR
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.12.02.20242719
DO 10.1101/2020.12.02.20242719
A1 Nykamp, Keith
A1 Truty, Rebecca
A1 Riethmaier, Darlene
A1 Wilkinson, Julia
A1 Bristow, Sara L.
A1 Aguilar, Sienna
A1 Neitzel, Dana
A1 Faulkner, Nicole
A1 Kahan, Stephanie
A1 Aradhya, Swaroop
YR 2020
UL http://medrxiv.org/content/early/2020/12/04/2020.12.02.20242719.abstract
AB Purpose To evaluate the risk and spectrum of phenotypes associated in individuals with one or two of the CFTR T5 haplotype variants (TG11T5, TG12T5 and TG13T5) in the absence of the R117H variant.Methods Individuals who received testing with CFTR NGS results between 2014 and 2019 through Invitae at ordering provider discretion were included. TG-T repeats were detected using a custom-developed haplotype caller. Frequencies of the TG-T5 variants (biallelic or in combination with another CF-causing variant [CFvar]) were calculated. Clinical information reported by the ordering provider (via requisition form) or the individual (during genetic counseling appointments) was examined.Results Among 548,300 individuals, the minor allele frequency of the T5 allele was 4.2% (TG repeat distribution: TG11=68.1%, TG12=29.5%, TG13=2.4%). When present with a CFvar, each of the TG[11-13]T5 variants were significantly enriched in individuals with a “high suspicion” of CF/CFTR-RD (personal/family history of CF/CFTR-RD) compared to those with very “low suspicion” for CF or CFTR-RD (hereditary cancer testing, CFTR not requisitioned). Compared to CFvar/CFvar individuals, TG[11-13]T5/CFvar individuals generally had single organ involvement, milder symptoms, variable expressivity, and reduced penetrance.Discussion Data from this study provides a better understanding of disease risks associated with inheriting TG[11-13]T5 variants and has important implications for reproductive genetic counseling.Competing Interest StatementAll authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare the following. KN, RT, DR, JW, SLB, SA, DN, NF, SK, SA are employed by and shareholders in Invitae. No funding and no other relationships or activities that could appear to have influenced the submitted work.Funding StatementNo external funding was received.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Review and analysis of de-identified data were approved for waiver of authorization and granted exempt status by the Western Institutional Review Board.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available from the corresponding author upon reasonable request.